KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Chemed (CHE) over the last 14 years, with Q3 2025 value amounting to $81000.0.

  • Chemed's Amortization of Deferred Charges changed 0.0% to $81000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $321000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $321000.0 for FY2024, which is 4465.52% down from last year.
  • As of Q3 2025, Chemed's Amortization of Deferred Charges stood at $81000.0, which was down 0.0% from $80000.0 recorded in Q2 2025.
  • In the past 5 years, Chemed's Amortization of Deferred Charges ranged from a high of $325000.0 in Q2 2023 and a low of $76000.0 during Q1 2021
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $80000.0 (2023), whereas its average is $94210.5.
  • As far as peak fluctuations go, Chemed's Amortization of Deferred Charges skyrocketed by 32207.79% in 2023, and later crashed by 7538.46% in 2024.
  • Chemed's Amortization of Deferred Charges (Quarter) stood at $77000.0 in 2021, then grew by 23.38% to $95000.0 in 2022, then dropped by 15.79% to $80000.0 in 2023, then changed by 0.0% to $80000.0 in 2024, then rose by 1.25% to $81000.0 in 2025.
  • Its Amortization of Deferred Charges was $81000.0 in Q3 2025, compared to $80000.0 in Q2 2025 and $80000.0 in Q1 2025.